Pages that link to "Q38176242"
Jump to navigation
Jump to search
The following pages link to Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. (Q38176242):
Displaying 50 items.
- Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances (Q26745338) (← links)
- Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? (Q26766689) (← links)
- Unique genomic profile of fibrolamellar hepatocellular carcinoma (Q27853116) (← links)
- Genetic alterations in hepatocellular carcinoma: An update (Q28073241) (← links)
- Gender Differences in Adipocyte Metabolism and Liver Cancer Progression (Q28078472) (← links)
- A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells (Q28553513) (← links)
- TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma (Q30987443) (← links)
- Integrative Analysis of Microarray Data to Reveal Regulation Patterns in the Pathogenesis of Hepatocellular Carcinoma (Q31117540) (← links)
- Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma (Q33730678) (← links)
- Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. (Q33807832) (← links)
- Liver cancer: Approaching a personalized care (Q35903794) (← links)
- The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling (Q36048511) (← links)
- Leveraging a Multi-Omics Strategy for Prioritizing Personalized Candidate Mutation-Driver Genes: A Proof-of-Concept Study. (Q36343345) (← links)
- Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib (Q36356419) (← links)
- Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. (Q36922232) (← links)
- Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. (Q36927013) (← links)
- HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: A retrospective case-control study (Q37164927) (← links)
- Dual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen (Q37317562) (← links)
- Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo (Q37362725) (← links)
- Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing (Q37457920) (← links)
- Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. (Q37580172) (← links)
- Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease (Q37610670) (← links)
- Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways (Q37681728) (← links)
- The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. (Q38246712) (← links)
- Tivantinib: critical review with a focus on hepatocellular carcinoma. (Q38259343) (← links)
- New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions (Q38282800) (← links)
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era. (Q38521011) (← links)
- HBx-mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis (Q38744233) (← links)
- MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development (Q38823802) (← links)
- Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents (Q38856299) (← links)
- Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis (Q38895324) (← links)
- Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists (Q39307416) (← links)
- Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma (Q39366121) (← links)
- Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma (Q40060996) (← links)
- Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options (Q40218092) (← links)
- Therapeutic strategies for hepatocellular carcinoma: new advances and challenges (Q41191439) (← links)
- Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells (Q41547180) (← links)
- Modeling human liver cancer heterogeneity: virally induced transgenic models and mouse genetic models of chronic liver inflammation (Q41636479) (← links)
- Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2. (Q41774349) (← links)
- A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma (Q42064611) (← links)
- Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future (Q42343451) (← links)
- The utility of biomarkers in hepatocellular carcinoma: review of urine-based 1H-NMR studies - what the clinician needs to know. (Q47162797) (← links)
- Chemotherapy for hepatocellular carcinoma: current status and future perspectives (Q47775953) (← links)
- The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. (Q48287375) (← links)
- A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma (Q49960144) (← links)
- Liver cancer: time to evolve trial design after everolimus failure. (Q54332985) (← links)
- Predicting hepatocellular carcinoma through cross-talk genes identified by risk pathways. (Q55035102) (← links)
- Predicting hepatocellular carcinoma development for cirrhosis patients via methylation detection of heparocarcinogenesis-related genes. (Q55345013) (← links)
- 18β-Glycyrrhetinic-acid-mediated unfolded protein response induces autophagy and apoptosis in hepatocellular carcinoma. (Q55367835) (← links)
- Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties. (Q55387948) (← links)